Nes-Ziona, Israel, Jan 1, 2019 – Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that Odelia Ben-Shitrit was appointed Director of Clinical Operations. Mrs. Shitrit joins Enlivex from Teva Pharmaceuticals, where she served as Global Senior Clinical Manager of Ajovy, an episodic and chronic migraine biologic drug – which recently received FDA marketing approval.
While at Teva Pharmaceuticals, Mrs. Ben Shitrit led a successful completion of two 2 global pivotal Phase III studies of Ajovy in episodic and chronic migraine, and submission of the marketing application to both the FDA and the European Medicinal Authority (EMA).
Previously, Mrs. Ben-Shitrit worked for more than 17 years in various senior positions, including Line Manager of Clinical Operations, Clinical Lead and Senior Clinical Research Associate for PAREXEL International. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries, and has approximately 18,900 employees. PAREXEL provides comprehensive regulatory expertise and Phase I-IV clinical trial management services.
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.